GLP-1SG 10mg
GLP-1SG 10mg is a synthetic research peptide designed for laboratory investigation of glucagon-like peptide-1 (GLP-1) receptor signaling, incretin biology, glucose-regulatory pathways, metabolic signaling, and related cellular processes.
GLP-1SG corresponds to the research compound semaglutide, a modified GLP-1 analog extensively studied for its interaction with the GLP-1 receptor. Its molecular structure has made it an important research tool for investigating prolonged GLP-1 receptor activation and the biochemical pathways associated with incretin signaling.
GLP-1SG 10mg is supplied strictly for laboratory research and analytical investigation. It is not intended for human or animal consumption, clinical use, diagnostic use, therapeutic use, or veterinary use.
Research Specifications
|
|
| Product Name |
GLP-1SG |
| Vial Quantity |
10mg |
| Form |
Lyophilized Powder |
| Research Classification |
GLP-1 Receptor Agonist Research Peptide |
| Primary Research Target |
GLP-1 Receptor (GLP-1R) |
| Research Pathways |
Incretin & Metabolic Signaling |
| Molecular Formula |
C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight |
4,113.6 g/mol |
| Research Identity |
Semaglutide |
| CAS Number |
910463-68-2 |
| Intended Use |
Laboratory Research Only |
GLP-1 Receptor Research
GLP-1SG is studied in relation to the glucagon-like peptide-1 receptor (GLP-1R), a G-protein-coupled receptor involved in metabolic and endocrine signaling.
Naturally occurring GLP-1 is an incretin hormone released primarily by intestinal L cells in response to nutrient exposure. Interaction between GLP-1 and GLP-1R initiates intracellular signaling pathways that have been extensively investigated in relation to pancreatic endocrine activity, nutrient-responsive signaling, and metabolic regulation.
Modified GLP-1 receptor agonists provide researchers with tools for examining receptor activation, intracellular signaling, and downstream biochemical responses under controlled experimental conditions.
Incretin Signaling Research
A major area of GLP-1 research involves the incretin system.
Incretins are signaling hormones associated with physiological responses to nutrient exposure. GLP-1 represents one of the principal hormones studied within this system and has been investigated extensively in relation to glucose-dependent endocrine signaling.
Research involving semaglutide and related GLP-1 receptor agonists has contributed substantially to the scientific understanding of prolonged GLP-1 receptor activation and downstream incretin signaling.
Laboratory investigation of these compounds allows researchers to examine receptor activation, intracellular signaling, and related metabolic pathways within controlled experimental systems.
Glucose-Regulatory Pathway Research
GLP-1 receptor signaling has been studied extensively in experimental models involving glucose homeostasis and pancreatic endocrine activity.
Activation of GLP-1R can initiate intracellular signaling involving cyclic adenosine monophosphate (cAMP) and associated downstream mechanisms. These pathways have been investigated for their roles in glucose-dependent cellular responses and endocrine signaling.
Laboratory investigation of GLP-1 receptor agonists therefore provides a framework for studying relationships among receptor activation, intracellular signaling, endocrine-cell activity, and metabolic regulation.
These pathways remain areas of experimental investigation and should not be interpreted as establishing therapeutic effects for research materials.
Metabolic Signaling Research
Research involving GLP-1 extends beyond pancreatic signaling.
GLP-1 receptors and GLP-1-associated pathways have been investigated across multiple biological systems, including experimental models involving the gastrointestinal tract, central nervous system, pancreatic tissue, and other metabolically active systems.
This broad signaling network has made GLP-1R an important research target for investigating communication among nutrient sensing, endocrine signaling, and central metabolic regulatory pathways.
Research involving modified GLP-1 analogs has also provided scientists with models for investigating how sustained receptor activity can influence downstream cellular signaling.
Molecular Research Profile
GLP-1SG corresponds to semaglutide, a structurally modified GLP-1 analog engineered to retain activity at the GLP-1 receptor while possessing molecular characteristics distinct from endogenous GLP-1.
The molecular formula is:
C₁₈₇H₂₉₁N₄₅O₅₉
with a molecular weight of approximately:
4,113.6 g/mol
Semaglutide is structurally related to native GLP-1 but incorporates specific molecular modifications that alter its biochemical characteristics. These include amino-acid substitutions and attachment of a lipid-containing side chain.
These structural characteristics have made the molecule particularly useful for laboratory research examining relationships among peptide structure, receptor interaction, molecular stability, and duration of signaling activity.
The CAS Registry Number associated with semaglutide is 910463-68-2.
GLP-1 Analog Research
Synthetic GLP-1 analogs represent an important class of research compounds because targeted structural modifications can substantially influence their biochemical properties.
Researchers have used modified GLP-1 analogs to investigate receptor binding, receptor activation, intracellular signaling, peptide stability, and structure-activity relationships.
GLP-1SG provides research material for continued laboratory investigation of these pathways and the broader molecular biology associated with GLP-1 receptor signaling.
Lyophilized Research Peptide
GLP-1SG 10mg is supplied in lyophilized powder form for laboratory research.
Lyophilization removes water from the material under controlled conditions, producing a stable dry research format suitable for storage and subsequent laboratory preparation according to established research protocols.
Batch-specific analytical documentation may be available to provide additional information regarding the identity and purity of the research material.
Research Use Only
GLP-1SG 10mg is intended strictly for laboratory research purposes only.
This product is not intended for human consumption, animal consumption, clinical use, diagnostic use, therapeutic use, veterinary use, or for the treatment, cure, mitigation, or prevention of any disease.
